雲南白藥(000538.SZ):第一大股東引入中國人壽資產增資90億元、已收到首筆增資款
格隆匯6月14日丨雲南白藥(000538.SZ)公佈,2022年6月13日,公司收到公司並列第一大股東雲南省國有股權運營管理有限公司(“國有股權公司”)發來的《吿知函》,獲悉國有股權公司控股股東雲南省投資控股集團有限公司(“雲投集團”)與中國人壽資產管理有限公司(“中國人壽”)、國有股權公司於2022年5月26日簽署了《雲南省國有股權運營管理有限公司增資協議》,協議約定由中國人壽向國有股權公司增資,增資比例24.79%,增資金額90億元。2022年6月13日,國有股權公司已收到首筆增資款項。
國有股權公司的股權結構,增資前,由雲投集團持股100%;增資後,由雲投集團持股75.21%,中國人壽持股24.79%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.